drugset / Trial / NCT05263934
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Timeline
- Start
- 2022-07-14
- Primary completion
- 2026-09-29
- Completion
- 2026-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Depemokimab | Protein / enzyme biologic | — | — |
| Comparator | Mepolizumab | Monoclonal antibody | — | — |